Substance / Medication

Procainamide hydrochloride

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Research Evidence

Published studies and systematic reviews

Sort:
Data standards for atrial fibrillation/flutter and catheter ablation: the European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart).
Batra Gorav, Aktaa Suleman, Camm A John et al. · Eur Heart J Qual Care Clin Outcomes · 2023
PMID: 36243903Meta-AnalysisFull text (PMC)
Anomalous electrical conductivity behavior at elevated pressure in the protic ionic liquid procainamide hydrochloride.
Wojnarowska Z, Roland C M, Swiety-Pospiech A et al. · Phys Rev Lett · 2012
PMID: 22304270Other
Potentiation of cisplatin-induced antiproliferative and apoptotic activities by the antiarrhythmic drug procainamide hydrochloride.
Viale Maurizio, Fenoglio Carla, de Totero Daniela et al. · Pharmacol Rep · 2016
PMID: 27026293Preclinical
Preparation and Antiproliferative Activity of Liposomes Containing a Combination of Cisplatin and Procainamide Hydrochloride.
Viale Maurizio, Fontana Antonella, Maric Irena et al. · Chem Res Toxicol · 2016
PMID: 27501273Preclinical
Synthesis, characterization, and assessment of cytotoxic, antiproliferative, and antiangiogenic effects of a novel procainamide hydrochloride-poly(maleic anhydride-co-styrene) conjugate.
Karakus Gulderen, Akin Polat Zubeyde, Sahin Yaglıoglu Ayse et al. · J Biomater Sci Polym Ed · 2013
PMID: 23713427Preclinical
Study of feasibility of the treatment with procainamide hydrochloride and cisplatin in pregnant mice.
Ognio Emanuela, Chiavarina Barbara, Peterka Miroslav et al. · Chem Biol Interact · 2006
PMID: 17084828Preclinical
Reduction of cisplatin hepatotoxicity by procainamide hydrochloride in rats.
Zicca Antonio, Cafaggi Sergio, Mariggiò Maria A et al. · Eur J Pharmacol · 2002
PMID: 12065080Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Procainamide hydrochloride (substance)
SNOMED CT
25254000
UMLS CUI
C0600311

Clinical Data

This intervention maps to 12 entities in the Ltrl knowledge graph.

7
Conditions
2
Biomarkers
2
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.